His recent cross-disciplinary imaging research in unstable brain aneurysm models brings together interventional neuroradiologists, neurosurgeons, chemists and bioengineers; an endeavor that has resulted in landmark papers in Radiology and Stroke and funding from the NINDS.
His important contributions to basic and translational imaging science include:
1) Synthesis and clinical trials of the first 100% synthetic macromolecular imaging agent; 2) The first demonstration of in vivo imaging of proteolysis in solid tumors using optical imaging sensors (“in vivo enzymology”); 3) Comparison of targeted and non-targeted delivery to tumors in animal models; 4) The first in vivo imaging of viral/non-viral gene delivery vectors and magnetic resonance imaging of tyrosinase as a marker of gene expression; 5) Development and in vivo use of peroxidase substrates/MR imaging sensors; 6) Targeted delivery of superparamagnetic nanoparticles to brain tumors and to endothelial markers for adoptive cell transfer research; 7) Quantitative imaging of anti-angiogenesis in cancer models.
Dr. Bogdanov published more than 160 full papers in peer-reviewed journals, has been invited to give more than 100 lectures and seminars both nationally and internationally, and has contributed numerous reviews and book chapters to the scientific literature. Of his peer reviewed papers, more than 30 have been cited more than 100 times (h-index 59).
Dr. Bogdanov is the inventor on thirteen issued US patents most of which were licensed to Visen Medical (acquired by Perkin-Elmer); Sanofi and PharmaIN Corp. (Bothell WA), a drug delivery company he co-founded in 2001.